Video

Weight loss intervention improves quality of life in breast cancer survivors

Weight loss intervention improves quality of life in breast cancer survivors

1 June 2026
Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma

1 June 2026
Multi-cancer early detection (MCED) blood test reduces stage IV cancer and boosts early detection in population screening

MCED blood test trial fails primary end point, but screening cut number of cancers found at stage IV

1 June 2026
Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL

1 June 2026
177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC

1 June 2026
GLP-1 use linked to improved survival in patients with cancer

GLP-1 use linked to improved survival in patients with cancer

1 June 2026
Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic disease in uveal melanoma

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma

1 June 2026
Olaparib plus pembrolizumab improves response but not PFS in BRCA-mutant pancreatic cancer

Olaparib plus pembrolizumab improves response but not PFS in BRCA-mutant pancreatic cancer

1 June 2026
Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps

Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps

1 June 2026
Novel therapies in the evolving mCRPC treatment landscape

Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC

1 June 2026
Tarlatamab improves brain metastases control and survival compared to chemotherapy in small cell lung cancer

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC

1 June 2026
Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma

1 June 2026
Back to Top